Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations

Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.

Big data concept. 3D .Thousands bar graphs forming words big data
Sanofi's agreement with Google is among several it's made with analytics partners

A few months ahead of incoming CEO Paul Hudson’s start at Sanofi, the French pharma is undertaking a big data collaboration with Google that it hopes can help its R&D engine work more efficiently toward personalized medicine while also applying analytics to its commercial operation. The two companies announced their alliance centered around creating a “virtual innovation lab” on 18 June. No financial terms nor the length of the agreement were disclosed.

Details on the partnership are scant at present, but the alliance apparently is not between Sanofi and Google’s health care spinout Verily Life Sciences LLC. Those two entities teamed up in 2016 to create a diabetes-focused joint venture called Onduo, with the partners jointly investing $500m in the effort

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

More from Business

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By 

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.